91 – 100 of 153
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies
(
- Contribution to journal › Article
-
Mark
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
(
- Contribution to journal › Article
-
Mark
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
-
Mark
Associations between the APOE-ε2 and APOE-ε4 alleles with resistance and resilience against Alzheimer's disease pathology
(
- Contribution to journal › Article
-
Mark
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review